These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16753343)

  • 1. CCR5: no longer a "good for nothing" gene--chemokine control of West Nile virus infection.
    Lim JK; Glass WG; McDermott DH; Murphy PM
    Trends Immunol; 2006 Jul; 27(7):308-12. PubMed ID: 16753343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genetic basis for human susceptibility to West Nile virus.
    Diamond MS; Klein RS
    Trends Microbiol; 2006 Jul; 14(7):287-9. PubMed ID: 16750369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety concerns about CCR5 as an antiviral target.
    Telenti A
    Curr Opin HIV AIDS; 2009 Mar; 4(2):131-5. PubMed ID: 19339952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR5 deficiency increases risk of symptomatic West Nile virus infection.
    Glass WG; McDermott DH; Lim JK; Lekhong S; Yu SF; Frank WA; Pape J; Cheshier RC; Murphy PM
    J Exp Med; 2006 Jan; 203(1):35-40. PubMed ID: 16418398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR5 antagonists: a new tool in fighting HIV.
    Jülg B; Goebel FD
    J HIV Ther; 2005 Dec; 10(4):68-71. PubMed ID: 16519245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR5 antagonists for the treatment of HIV.
    Barber CG
    Curr Opin Investig Drugs; 2004 Aug; 5(8):851-61. PubMed ID: 15600241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection.
    Glass WG; Lim JK; Cholera R; Pletnev AG; Gao JL; Murphy PM
    J Exp Med; 2005 Oct; 202(8):1087-98. PubMed ID: 16230476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR5 limits cortical viral loads during West Nile virus infection of the central nervous system.
    Durrant DM; Daniels BP; Pasieka T; Dorsey D; Klein RS
    J Neuroinflammation; 2015 Dec; 12():233. PubMed ID: 26667390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics.
    Suresh P; Wanchu A
    J Postgrad Med; 2006; 52(3):210-7. PubMed ID: 16855325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.
    Maeda K; Nakata H; Ogata H; Koh Y; Miyakawa T; Mitsuya H
    Curr Opin Pharmacol; 2004 Oct; 4(5):447-52. PubMed ID: 15351348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tropism switch in patients infected with HIV-1 and its clinical implications for the treatment with CCR5-receptor inhibitors.
    Arastéh K; Stocker H
    Eur J Med Res; 2007 Oct; 12(9):397-402. PubMed ID: 17933720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CCR5 antagonists: a new class of antiretrovirals].
    Peytavin G; Calvez V; Katlama C
    Therapie; 2009; 64(1):9-16. PubMed ID: 19463248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic.
    Lim JK; Louie CY; Glaser C; Jean C; Johnson B; Johnson H; McDermott DH; Murphy PM
    J Infect Dis; 2008 Jan; 197(2):262-5. PubMed ID: 18179388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A moving target: the multiple roles of CCR5 in infectious diseases.
    Klein RS
    J Infect Dis; 2008 Jan; 197(2):183-6. PubMed ID: 18179384
    [No Abstract]   [Full Text] [Related]  

  • 17. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection.
    Anderson J; Akkina R
    Gene Ther; 2007 Sep; 14(17):1287-97. PubMed ID: 17597795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms.
    Dolan MJ; Kulkarni H; Camargo JF; He W; Smith A; Anaya JM; Miura T; Hecht FM; Mamtani M; Pereyra F; Marconi V; Mangano A; Sen L; Bologna R; Clark RA; Anderson SA; Delmar J; O'Connell RJ; Lloyd A; Martin J; Ahuja SS; Agan BK; Walker BD; Deeks SG; Ahuja SK
    Nat Immunol; 2007 Dec; 8(12):1324-36. PubMed ID: 17952079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. West Nile virus encephalitis infection in a heart transplant recipient: a case report.
    Bragin-Sánchez D; Chang PP
    J Heart Lung Transplant; 2005 May; 24(5):621-3. PubMed ID: 15896763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.